-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Triple-negative breast cancer (TNBC) is a heterogeneous group of breast cancers defined by deletions of ER, PR and Her2
Triple-negative breast cancer (TNBC) is a heterogeneous group of breast cancers defined by deletions of ER, PR and Her2
Currently, in the adjuvant setting, the main systemic treatment option for TNBC is multi-agent chemotherapy
Immunotherapy is now approved for PD-L1+ metastatic TNBC patients as well as for the neoadjuvant treatment of TNBC; but even in PD-L1+ patients, responses are different
Image credit: https://pubmed.
Image credit: https://pubmed.
Recently, researchers at Baylor College of Medicine published an article titled "Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer" in the journal Cancer research.
Immunosuppressive components of the tumor microenvironment, such as tumor-associated macrophages (TAMs), can provide barriers to successful antitumor responses by cytolytic T cells
The therapeutic combination was effective against several highly aggressive TNBC mouse models of breast tumor and lung metastasis
Transcriptional and metabolic heterogeneity of TAMs was also characterized in two closely related hypo/mesenchymal subtype tumor models with distinct therapeutic responses
Combination therapy leads to expansion of CD8+/CD4+ T and B cells in reactive T12 tumors
Combination therapy leads to expansion of CD8+/CD4+ T and B cells in reactive T12 tumorsImage credit: https://pubmed.
Image credit: https://pubmed.
This study also further underscores the need to further understand the heterogeneity of immune cell subsets
references
Swarnima Singh et al.
Swarnima Singh et al.
Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer.
Cancer Res.
2022 Apr 20; canres.
3714.
2021.
doi: 10.
1158/0008-5472.
CAN- 21-3714.
Leave a message here
